Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Pembrolizumab |
| Indication/Tumor Type | gastroesophageal junction adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Phase II | Actionable | In a Phase II trial (KEYNOTE-059) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in an objective response rate of 15.5% (23/148, complete response 3, partial response 20) with a median response duration of 16.3 months in patients with CD274 (PD-L1)-positive (CPS >=1) gastric cancer or gastroesophageal junction adenocarcinoma (PMID: 29543932; NCT02335411). | 29543932 |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for patients with ERBB2 (HER2)-negative, metastatic gastroesophageal junction cancer with CD274 (PD-L1) expression, especially for those with higher levels of tumor CD274 (PD-L1) expression (PMID: 38458658; ESMO.org). | detail... 38458658 |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib tiral, Keytruda (pembrolizumab) treatment resulted in partial response in 22% (8/36) of patients with CD274 (PD-L1)-positive gastric and gastroesophageal junction adenocarcinoma (PMID: 27157491). | 27157491 |
| CD274 positive | gastroesophageal junction adenocarcinoma | sensitive | Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) is included in guidelines as first-line therapy for patients with advanced or metastatic gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10) (PMID: 35914639; ESMO.org). | 35914639 detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27157491) | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. | Full reference... |
| (29543932) | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. | Full reference... |
| ESMO Clinical Practice Guidelines | Full reference... | |
| ESMO Clinical Practice Guidelines | Full reference... | |
| (35914639) | Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Full reference... |
| (38458658) | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer. | Full reference... |